Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 30, 2021 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma and FUJIFILM Diosynth Biotechnologies Announce Manufacturing Agreement for aTyr’s Lead Therapeutic Candidate ATYR1923

SAN DIEGO, Nov. 30, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
November 12, 2021 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma to Present at Upcoming Investor Conferences in November

SAN DIEGO, Nov. 12, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
November 10, 2021 16:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Third Quarter 2021 Results and Provides Corporate Update

Positive results reported from Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis provided proof-of-concept for ATYR1923 and validation for tRNA synthetase biology platform and NRP2...
November 03, 2021 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma to Webcast Conference Call Reporting Third Quarter 2021 Financial Results

SAN DIEGO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
October 11, 2021 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma to Participate in Piper Sandler Investor Lung Day

SAN DIEGO, Oct. 11, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
October 06, 2021 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Appointment of Robert W. Ashworth, PhD, as Vice President of Regulatory Affairs

SAN DIEGO, Oct. 06, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
September 20, 2021 16:07 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Closing of $86.3 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

SAN DIEGO, Sept. 20, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines based on...
September 16, 2021 16:01 ET | Source: aTyr Pharma, Inc.

aTyr Pharma to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit

SAN DIEGO, Sept. 16, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
September 15, 2021 16:01 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Proposed Public Offering of Common Stock

SAN DIEGO, Sept. 15, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines based on...
September 13, 2021 07:30 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Positive Data from Phase 1b/2a Clinical Trial Demonstrating Consistent Dose Response for ATYR1923 in Pulmonary Sarcoidosis

Trial met primary endpoint, ATYR1923 was safe and well-tolerated. Efficacy observed in key endpoints including steroid reduction of 58% in the 5.0 mg/kg treatment group with 33% of patients in the...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right